Variant: rs11554290 

    present in Gene: NRAS
    present in Chromosome: 1
    Position on Chromosome: 114713908
    Alleles of this Variant: T/A;C;G

rs11554290 in NRAS gene and Adenocarcinoma of lung (disorder) PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Adrenocortical carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Brain Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Chronic Lymphocytic Leukemia PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Colorectal Neoplasms PMID 20736745 2010 NRAS mutations are rare in colorectal cancer.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 21305640 2011 Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

PMID 17699718 2007 AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.

PMID 21729679 2011 Development of molecular biomarkers in individualized treatment of colorectal cancer.

PMID 20619739 2010 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

PMID 16273091 2006 BRAF mutation predicts sensitivity to MEK inhibition.

PMID 21829508 2011 PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

rs11554290 in NRAS gene and Cutaneous Melanoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Gastric Adenocarcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Glioblastoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Leukemia, Myelocytic, Acute PMID 16434492 2006 Implications of NRAS mutations in AML: a study of 2502 patients.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 19075190 2009 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

PMID 2278970 1990 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.

PMID 22407852 2012 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

PMID 3122217 1987 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

rs11554290 in NRAS gene and Liver carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Malignant Uterine Corpus Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Multiple Myeloma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Nasopharyngeal Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Non-Small Cell Lung Carcinoma PMID 14508525 2003 BRAF mutations in papillary carcinomas of the thyroid.

PMID 22773810 2012 Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

PMID 19880792 2010 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

PMID 23515407 2013 Characteristics of lung cancers harboring NRAS mutations.

PMID 18948947 2008 Somatic mutations affect key pathways in lung adenocarcinoma.

PMID 1654209 1991 ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 6587382 1984 Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.

PMID 24370118 2014 Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.

rs11554290 in NRAS gene and Renal Cell Carcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Serous cystadenocarcinoma ovary PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Thyroid Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and Transitional cell carcinoma of bladder PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs11554290 in NRAS gene and melanoma PMID 16291983 2005 Distinct sets of genetic alterations in melanoma.

PMID 20130576 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

PMID 2674680 1989 N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 8120410 1994 Ras mutations in human melanoma: a marker of malignant progression.

PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

PMID 20149136 2010 Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions.

PMID 23569304 2013 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

PMID 18390968 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

PMID 23538902 2013 Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

PMID 20406486 2010 Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

PMID 23414587 2013 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

PMID 20179705 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

PMID 22761467 2012 First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

PMID 21576590 2011 NRAS-mutant melanoma: response to chemotherapy.

PMID 21107323 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.